Multiple Sclerosis: The Everyday Complaints That May Show Up 15 Years Before The First Classic Symptom
(© Prostock-studio – stock.adobe.com) In A Nutshell A Long Lead-In: People later diagnosed with MS in British Columbia…
Early B-cell therapy linked to better MS disease control
For people recently diagnosed with multiple sclerosis (MS), early treatment choices were associated with only slight differences after…
Autoimmune diseases form distinct genetic clusters, study finds
Different autoimmune diseases often share genetic risk factors, but not through a single common genetic vulnerability. In a…
MS patients’ quality of life associated with walking performance and functional capacity
A study by the University of Eastern Finland found that quality of life in people with multiple sclerosis…
Emergency diagnoses of medical conditions predict worse patient survival
Patients diagnosed with conditions after an emergency hospital admission or an emergency room visit face a higher risk…
Multiple sclerosis mortality trends underscore need for comprehensive patient care
An analysis of more than 42,000 U.S. deaths linked to multiple sclerosis (MS) found that death rates varied…
Multiple sclerosis patients given PBS lifeline amid drug pricing dispute
Life-changing drugs used to treat multiple sclerosis (MS) will remain subsidised for Australians as Labor pledges to resolve…
Novel salvage surgical approach for refractory multiple sclerosis-related trigeminal neuralgia
A case report in Chinese Neurosurgical Journal describes a novel salvage surgical approach for refractory multiple sclerosis-related trigeminal…
New gene therapy strategy uses the brain’s own glymphatic transport system for drug delivery
A new study describes a gene therapy strategy that uses the brain’s own glymphatic transport system to distribute…
PBS dispute could leave MS patients with huge bills for crucial drugs Ocrevus and Kesimpta
A dispute over how Australia prices medicines has sparked fears 10,000 people with multiple sclerosis will be forced…
Low-cost B-cell depleting therapy is as effective as standard treatment for multiple sclerosis
A Norwegian Swedish clinical trial published in the New England Journal of Medicine (NEJM) demonstrates that rituximab, a…
Ocrelizumab slows disability progression in advanced progressive multiple sclerosis
A major international phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab…